LY-171883 (88107-10-2) is a selective and orally active leukotriene D4 (LTD4) antagonist (Ki = 0.63 μM).1 It is also an activator of peroxisome proliferator-activated receptors (PPARs).2,3
This product is a brown viscous liquid with good cleaning and anti-rust capabilities.
LY 171883 is a selective leukotriene D4 antagonist.
ChEBI: A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti
asthmatic activity.
Selective, orally active leukotriene D 4 (LTD 4 ) antagonist; inhibits binding of [ 3 H]-LTD 4 to guinea pig lung membranes (K i = 0.63 μ M).? Acts as an agonist at peroxisome proliferator-activated receptors (PPARs).
Ingredients: weighing oleic acid and triethanolamine with a mass ratio of 2:1;
Stirring: put the dosed materials and toluene into the reactor, and then pass into the nitrogen bubbling and stirring, the nitrogen plays the role of protection;
Heating: heating the reaction kettle, heating the first in 3 hours to 120 ??, hold for 1 hour, and then heat up to 160 ?? and then hold, when there is no water generated to stop heating;
Cooling the finished product: pass cooling water to cool to below 60??, then stop passing nitrogen to make the finished product.
in gh(3) cells, ly-171883 was able to reversibly increase the amplitude of ca(2+)-activated k(+) current concentration-dependently with an ec(50) value of 15 μm. moreover, the treatment of ly-171883 to cytosolic face did not affect single channel conductance of large-conductance ca(2+)-activated k(+) channels in excised inside-out patches recorded from gh(3) cells, however, ly-171883 did increase the channel activity. in addition, the ly-171883-stimulated activity of bk(ca) channels was dependent on membrane potential [1].
the effect of ly-171883 on the respiratory and cardiovascular changes in endotoxemia was studied in unanesthetized sheep. in group one, ly-171883 at 4 mg/kg was i.v. injected. in group two, escherichia coli endotoxin (1 μg/kg) was infused, and in group three, ly-171883 at 4 mg/kg was administered before and after the same dose of endotoxin. results showed that infusion of ly-171883 in group one did not alter baseline ventilatory and cardiovascular measurements. in group two, a two-phase pulmonary response was found. an early pulmonary hypertension phase with a fall in cardiac index was observed in group three [2].
[1] J H FLEISCH. LY171883, 1-less than 2-hydroxy-3-propyl-4-less than 4-(1H-tetrazol-5-yl) butoxy greater than phenyl greater than ethanone, an orally active leukotriene D4 antagonist.[J]. Journal of Pharmacology and Experimental Therapeutics, 1985, 233 1: 148-157.
[2] PATRICIA S. FOXWORTHY Patrick I E. Effect of the peroxisome proliferator LY171883 on triglyceride accumulation in rats fed a fat-free diet[J]. Biochemical pharmacology, 1991, 42 7: Pages 1487-1491. DOI:
10.1016/0006-2952(91)90463-f[3] S A KLIEWER. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91 15: 7355-7359. DOI:
10.1073/pnas.91.15.7355
